Cardiovascular safety of fexofenadine HCl

American Journal of Cardiology

Volumn 83, Issue 10, 1999, Pages 1451-1454

  Pratt, Craig M ^a   Mason, Jolene ^b   Russell, Tanya ^b   Reynolds, Robert ^b   Ahlbrandt, Robert ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Hoechst Marion Roussel   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ERYTHROMYCIN; FEXOFENADINE; KETOCONAZOLE; PLACEBO; TERFENADINE;

ALLERGIC RHINITIS; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; TORSADE DES POINTES;

DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HISTAMINE ANTAGONISTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE;

EID: 0033562501     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00124-1     Document Type: Article

References (23)

1. Druce H.M., Kaliner M.A. Allergic rhinitis. JAMA. 259:1988;260-263.
2. Stafford C.T. Allergic rhinitis - a useful guide to diagnosis and treatment. Postgrad Med. 81:1987;147-157.
3. Tarnasky P.R., Van Arsdel P.P. Antihistamine therapy in allergic rhinitis. J Fam Pract. 30:1990;71-80.
4. Meltzer E.O. Antihistamine and decongestant-induced performance decrements. J Occup Med. 32:1990;327-334.
5. Lindquist M., Edwards I.R. Risks of nonsedating antihistamines (letter). Lancet. 349:1997;1322.
6. Meltzer E.O. Comparative safety of H1 antihistamines. Ann Allergy. 67:1991;625-633.
7. Woosley R.L. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol. 36:1996;233-252.
8. Hoechst Marion Roussel, Inc. Seldane. Physicians Desk Reference, Montvale NJ. 1997:1284-1286.
9. Janssen Pharmaceuticals Inc. Hismanal. Physicians Desk Reference, Montvale NJ. 1997:1341-1343.
10. Pratt C.M., Hertz R.P., Ellis B.E., Crowell S.P., Louv W., Moye L. Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over the counter antihistamines, ibuprofen and clemastine. Am J Cardiol. 73:1994;346-352.
11. Bernstein D., Schoenwetter W.F., Nathan R.A., Storms W., Ahlbrandt R., Mason J. Efficacy and safety of fexofenadine HCl for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 79:1997;443-448.
12. 1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc. 19:1998;135-141.
13. Bazett H.C. An analysis of the time-relations of electrocardiograms. Heart. 7:1920;353-370.
14. Fexofenadine HCl Integrated Summary of Safety, NDA 20-625. Data on file, Hoechst Marion Roussel, Kansas City, MO.
15. Honig P.K., Woolsey R.L., Zamani K., Conner D.P., Cantilena L.R. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmcol Ther. 52:1992;231-238.
16. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., Cantilena L.R. Terfenadine-ketoconazole interaction pharmacokinetic and electrocardiographic consequences . JAMA. 269:1993;1513-1518.
17. c interval on the scalar electrocardiogram Distinguishing drug effect from spontaneous variability . Am Heart J. 131:1996;472-480.
18. Mathews D.R., McNutt B., Okerholm R., Flicker M., McBride G. Torsade de pointes occurring in association with terfenadine use (Letter). JAMA. 266:1991;2375-2376.
19. Zimmerman M., Duruz H., Guinand O., Broccard O., Levy P., Lacatis D., Bloch A. Torsade de pointes after treatment with terfenadine and ketoconazole. Eur Heart J. 13:1992;1002-1003.
20. Bastecky J., Kvasnicka J., Vortel J., Tauchman M., Wasylivova V. Severe intoxication with antihistamines complicated by ventricular tachycardia. Intern Med. 3:1990;266-269.
21. Monahan B.P., Ferguson C.L., Killeavy E.S., Lloyd B.K., Troy J., Cantilena L.R. Torsade de pointes occurring in association with terfenadine use. JAMA. 264:1990;2788-2790.
22. Woosley R.L., Chen Y., Freiman J.P., Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 269:1993;1532-1536.
23. Rampe D., Wible B., Brown A.M., Dage R.C. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol. 44:1993;1240-1245.